Interestingly, the concentrations of LC3B in the kidneys of the CIS-treated Gal-3 KO mice were significantly higher than in the CIS-treated Gal-3 wild-type mice (p < 0.001) (Figure 4A). This evidence concerns the gene MAP1LC3B and in situ carcinoma.